Novel Drug Modalities DMPK Enabling Platforms
WuXi AppTec DMPK has extensive experience and established pharmacokinetics evaluation systems for ADC, PDC, Oligo, Peptide, mRNA, Covalent Drugs, Proteolysis Targeting Chimera (PROTAC*) pharmacokinetic studies based on the in vivo and in vitro pharmacokinetic studies platform – to help drug developers quickly advance their drug development projects.
-
Overview
-
Novel Drug Modalities
-
Related Resources
-
Related Services
Novel Drug Modalities
Overview
Our dedicated R&D team has summarized pharmacokinetic research strategies and established comprehensive evaluation solution from in vitro to in vivo for different novel drug modalities. The team consists of experts in different fields covering in vitro and in vivo ADME, metabolite identification, QWBA and radiolabeled mass balance, and bioanalysis.
We have collaborated with pharmaceutical and biotech companies focusing on new drug modalities. We have successfully supported thousands of projects and conducted extensive testing on tens of thousands of drug molecules, including peptides, antibodies, oligonucleotides, PROTACs, ADCs, PDCs, mRNA, Covalent Drugs, and etc.
Learn More
Novel Drug Modalities
-
PROTAC DMPK Services
Based on the pharmacokinetics evaluation systems for PROTAC molecules, WuXi AppTec DMPK has supported the screening of tens of thousands of PROTAC molecules and the IND applications of dozens of PROTAC molecules. In this process, we have formed a unique methodology for PROTAC pharmacokinetic studies - aimed at helping drug developers rapidly advance their PROTAC drug development projects.
-
ADC (Antibody-Drug Conjugate) DMPK Services
Based on the ADC integrated platform, WuXi AppTec DMPK has supported more than 200 ADCs for screening and more than 20 ADCs for IND filing. Throughout this process, we have accumulated extensive experience and can propose a specific DMPK strategy for each ADC project, which can effectively shorten the ADC development cycle.
-
Oligonucleotide Drugs DMPK Services
We have helped more than 70 global clients successfully screen and evaluate oligonucleotide pipelines, and have enabled dozens of oligonucleotide molecules’ IND applications, including ASO, siRNA, miRNA, and more. We not only have extensive experience in studying oligonucleotides but also have developed a specific methodology for the pharmacokinetic study of oligonucleotide drugs.
-
Peptide-Drug Conjugate (PDC) DMPK Services
Based on the characteristics of PDCs, the development strategy and assay condition of PDCs are customized according to our experience. WuXi AppTec DMPK has successfully supported more than 20 clients on PDC projects, including some IND-enabling studies.
-
Peptide Drugs DMPK Services
Based on the peptide integrated platform, WuXi AppTec DMPK has supported more than 140 global clients on peptide projects, including the screening of tens of thousands of peptide molecules and the IND applications of dozens of peptide molecules.
-
mRNA-Based Vaccines and Therapeutics Drugs DMPK Services
To facilitate the research and development of mRNA-based vaccines and therapeutics, WuXi AppTec DMPK has established an integrated bioanalytical platform. This platform includes qPCR, branched DNA (bDNA), ligand binding assays (LBA), liquid chromatography-mass spectrometry (LC-MS), and flow cytometry, enabling quantitative and semi-quantitative analysis of mRNA.
-
Covalent Drugs DMPK Services
The mechanism of covalent drugs is different from that of conventional small molecule drugs, which may bring corresponding challenges to the ADME studies, such as distribution and elimination studies. WuXi AppTec DMPK has established ADME platforms specially for covalent drugs. Up to now, WuXi AppTec DMPK has successfully supported nearly 100 covalent drug projects for clients and has successfully pushed many covalent drugs into clinical trials.
Related Resources
-
Advancing Antibody-Drug Conjugates (ADCs) with Novel Payloads and Their DMPK Considerations
ArticlesDec 10, 2024Learn More
-
Successful Prediction of Oral Pharmacokinetics of the KRAS G12C Inhibitor MRTX-849 in Humans Using PBPK Modeling
PostersDec 03, 2024Learn More -
Metabolite Identification in Peptide Drugs and Its Challenges
ArticlesDec 02, 2024Learn More -
Optimizing DMPK Strategy for Peptide Drugs
WebinarsNov 21, 2024Learn More -
Spotlight on the DMPK and Bioanalysis Strategy of Antibody Oligonucleotide Conjugates (AOCs)
ArticlesNov 21, 2024Learn More -
Exploring GLP-1 Receptor Agonists (GLP-1 RAs): R&D Advances and Tackling Bioanalytical Challenges
ArticlesNov 01, 2024Learn More -
DMPK Research of Cyclic Peptides
WebinarsOct 29, 2024Learn More -
Comparative Metabolite Profiling and Identification of a GalNAc-Conjugated siRNA, siRNA01, in Plasma Prepared with Various Anticoagulants, Serum, and In Vivo Plasma Using LC-UV-HRMS
PostersOct 25, 2024Learn More -
Decoding DMPK Profiles of 37 FDA-Approved Peptides: Insights and Radiolabeling Considerations
BlogsOct 18, 2024Learn More -
DMPK Properties and Research Platforms of Covalent Drugs
WebinarsOct 17, 2024Learn More -
In Vitro Metabolic Stability Evaluation of ADCs in Plasma and Whole Blood
PostersOct 17, 2024Learn More -
Establishment of Two In Vitro Glutathione Conjugation Models and Their Application in Covalent Drugs
ArticlesOct 12, 2024Learn More -
A Comprehensive Platform for Evaluating the In Vitro CYP Reaction Phenotyping of New Molecular Entities (NME)
PostersSep 26, 2024Learn More -
Comparative Metabolite Profiling and Identification of a GalNAc-Conjugated siRNA, siRNA01, in Plasma Prepared with Various Anticoagulants, Serum, and In Vivo Plasma Using LC-UV-HRMS
PostersSep 14, 2024Learn More -
Validation and Comprehensive Bioanalytical Strategy of In Vivo Studies for RNAI Therapeutics in Early Discovery
PostersSep 13, 2024Learn More -
How Radionuclide Drug Conjugates are Transforming Cancer Treatment
BlogsSep 06, 2024Learn More -
8 In Vitro Systems for Oligo Metabolism Study: Pros and Cons and Selection Suggestions
ArticlesAug 25, 2024Learn More -
A Novel Validated LC-MS/MS Approach for Simultaneous Determination of Total Antibody and Conjugated Payload for DS-8201 in SD Rat Serum
PostersAug 08, 2024Learn More -
A Rapid Liquid Chromatography-Mass Spectrometry Quantitation of Somatostatin in Rat Plasma
PostersJul 26, 2024Learn More -
Intrathecal Antisense Oligonucleotides: Pharmacokinetic Characteristics and Study Strategies
ArticlesJul 04, 2024Learn More -
Quantitative Analysis of a GalNAc-siRNA Conjugate and Its Metabolites Using Two-Dimensional Liquid Chromatography Coupled with Tandem Mass Spectrometry
PostersJul 04, 2024Learn More -
Plasma Protein Binding of Oligonucleotide Drugs: Implications, Methods and Strategies
ArticlesJun 27, 2024Learn More -
Novel DNA Purification Method Facilitates the Bioanalysis of DNA-Based Gene Therapeutics in Whole Blood Samples
PostersJun 20, 2024Learn More -
Webinar Q&A | DMPK Strategies in the Preclinical Development of Antibody-Drug Conjugates
BlogsJun 14, 2024Learn More -
Peptide-Radionuclide Conjugates: Interpretation of FDA Approved Drugs and DMPK Strategies
ArticlesJun 06, 2024Learn More -
Facilitating ADC Preclinical DMPK Research with an Integrated Bioanalysis Platform
WebinarsMay 24, 2024Learn More -
Webinar Q&A | Facilitating ADC Preclinical DMPK Research with an Integrated Bioanalysis Platform
BlogsMay 24, 2024Learn More -
Rapid EMSA: A New Method of Testing PPB in Oligonucleotides
BlogsApr 30, 2024Learn More -
Oligos for Ocular Diseases: Overcoming the Challenges
BlogsApr 11, 2024Learn More -
Research Strategy of Chiral PROTACs in Discovery Stage Based on Analysis Platforms of UPCC-MS/MS and UPLC-MS/MS
PostersMar 29, 2024Learn More -
DMPK Strategies in the Preclinical Development of Antibody-Drug Conjugates
WebinarsMar 25, 2024Learn More -
Development of a Convenient In Vitro Method for Predicting Metabolism and Disposition of Acrylamide Covalent Drugs in Humans
PostersMar 21, 2024Learn More -
Plasma Protein Binding of Oligonucleotides Using Rapid Agarose Gel Electrophoretic Mobility Shift Assay
PostersMar 15, 2024Learn More -
Metabolite Identification of Nucleoside Analog Prodrugs in Biological Matrix by Derivatization Coupled with Radio-Detector and Mass Spectrometry
PostersMar 07, 2024Learn More -
Quantitative Analysis of GalNAc-siRNA Conjugates in Tissue Homogenate Using Two-Dimensional Liquid Chromatography Coupled with Tandem Mass Spectrometry
PostersFeb 22, 2024Learn More -
Development of a Plasma Stability Assay of Oligonucleotides
PostersFeb 12, 2024Learn More -
A Comprehensive Bioanalytical Strategy of In Vivo Studies for RNAi Therapeutics in Early Discovery
PostersJan 31, 2024Learn More -
Effect of pH on Metabolite Profiling and Identification of GalNAc Conjugated siRNA in In Vitro Metabolic System
PostersJan 23, 2024Learn More -
Comparison of Branched DNA (B-DNA) and Polymerase Chain Reaction (RT-qPCR) Method Validation for the Quantification of mRNA Therapeutics in Plasma
PostersJan 12, 2024Learn More -
mRNA-Based Vaccines and Therapeutics Shorten the Development Cycle with WuXi AppTec DMPK Services
BrochuresJan 04, 2024Learn More -
What Can We Learn from the PK Profiles of FDA Approved mRNA Vaccines
BlogsDec 29, 2023Learn More -
Vaccine Development Driven by SARS-CoV-2: The Promising Prospect of mRNA Vaccines
BlogsDec 19, 2023Learn More -
Plasma Protein Binding of Nine Antisense Oligonucleotides by Ultrafiltration
PostersDec 19, 2023Learn More -
FDA Approved mRNA Vaccines: Interpretation of Preclinical Pharmacokinetic (PK) Data
ArticlesDec 19, 2023Learn More -
How to Conduct Preclinical Pharmacokinetic Evaluation of mRNA-Based Therapeutics?
BlogsDec 15, 2023Learn More -
What is mRNA Vaccines and Its Future?
ArticlesDec 08, 2023Learn More -
Strategies for Preclinical PK Evaluation of mRNA-Based Therapeutics: mRNA Vaccines, mRNA Therapeutic Drugs, and Novel Excipients
ArticlesDec 08, 2023Learn More -
The Advantage of LC-MS Method for Specific siRNA and It's Shortmer Quantitation to Support Mouse Liver Pharmacokinetics Study
PostersNov 30, 2023Learn More -
Unveiling the Future of Oligonucleotide Drugs: Overcoming Bioanalytical Challenges
BlogsNov 22, 2023Learn More -
The Role and Challenges of Plasma Protein Binding in Oligonucleotide Drug Development
ArticlesNov 22, 2023Learn More
Stay Connected
Keep up with the latest news and insights.
